What do systematic reviews say?

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1199 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1199 participants
  High

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 2283 participants
  Low

Prostacyclin vs control

Prostacyclin probably leads to lower mortality compared with control (moderate certainty).

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  OR 0.6 [0.38, 0.94]
  15 studies · 2554 participants
  Moderate

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1521 participants
  Low

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 271 participants
  Moderate

First‐line low‐dose thiazide vs placebo

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 19874 participants
  High

First‐line high‐dose thiazide vs placebo

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 15170 participants
  Low

First‐line beta‐blocker vs placebo

First‐line beta‐blocker showed no clear difference in total mortality compared with placebo (moderate certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.96 [0.86, 1.07]
  5 studies · 19313 participants
  Moderate

First‐line beta‐blocker vs placebo

First‐line beta‐blocker may leads to lower total stroke compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.83 [0.72, 0.97]
  5 studies · 19313 participants
  Low

First‐line beta‐blocker vs placebo

First‐line beta‐blocker showed no clear difference in total coronary heart disease compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.9 [0.78, 1.03]
  5 studies · 19313 participants
  Low

First‐line beta‐blocker vs placebo

First‐line beta‐blocker may leads to lower total cardiovascular events compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.89 [0.81, 0.98]
  5 studies · 19313 participants
  Low

First‐line beta‐blocker vs placebo

First‐line beta‐blocker may leads to higher withdrawal due to adverse effects compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 4.59 [4.11, 5.13]
  4 studies · 18565 participants
  Low

First‐line low‐dose thiazide vs placebo

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 19874 participants
  High

First‐line calcium channel blocker vs placebo

First‐line calcium channel blocker showed no clear difference in total mortality compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.86 [0.68, 1.09]
  1 study · 4695 participants
  Low

First‐line calcium channel blocker vs placebo

First‐line calcium channel blocker may leads to lower total stroke compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.58 [0.41, 0.84]
  1 study · 4695 participants
  Low

First‐line calcium channel blocker vs placebo

First‐line calcium channel blocker showed no clear difference in total coronary heart disease (CHD) compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.77 [0.55, 1.09]
  1 study · 4695 participants
  Low

First‐line calcium channel blocker vs placebo

First‐line calcium channel blocker may leads to lower total cardiovascular events compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.71 [0.57, 0.87]
  1 study · 4695 participants
  Low

First‐line low‐dose thiazide vs placebo

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 19022 participants
  High